Lori Ellen Fantry

Interests

Teaching

My teaching interests include primary care of HIV, HIV and women, HIV and opportunistic infections, HIV and chronic diseases, adult vaccines, sexually transmitted infections, and syphilis.

Research

My research interests include HIV and cancer, HIV and cardiovascular disease, HIV and women, HIV and osteoporosis, HIV Pre-Exposure Prophylaxis, and access to care in under-served populations.

Courses

Scholarly Contributions

Chapters

• Fantry, L. (2016). Gynecologic Infections. In University of Maryland Medical Center Antibiotic Guidelines(pp 34-42). Maryland: University of Maryland Medical Center.
• Fantry, L. (2016). Chronic Infections of the Small Intestine. In Yamada's Atlas of Gastroenterology, fifth edition(pp 177-183). Wiley-Blackwell.
• Fantry, L. (2015). Treponema Pallidum. In Antimicrobial Therapy and Vaccines, 3rd edition. Baltimore: Williams & Wilkins.
• Fantry, L. (2008). Chronic Infections of the Small Intestine. In Textbook of Gastroenterology, 2 Volume Set(pp 1225-44). Wiley-Blackwell; 5 edition (December 3, 2008).
• Fantry, L. (2009). Chronic Infections of the Small Intestine. In Atlas of Gastroenterology, 4th Edition(pp 318-2615). Wiley-Blackwell.
• Fantry, L. (2004). Hepatitis B. In The Health Care of Homeless Persons: A Manual of Communicable Diseases & Common Problems in Shelters & on the Streets(pp 35-39). Boston: The Boston Health Care for the Homeless Program (2004).
• Fantry, L. (2004). Hepititis A. In The Health Care of Homeless Persons: A Manual of Communicable Diseases & Common Problems in Shelters & on the Streets(pp 29-33). Boston: The Boston Health Care for the Homeless Program.
• Fantry, L. (2003). Chronic Infections of the Small Intestine. In Atlas of Gastroenterology, 3rd edition(pp 323-330). Philadelphia: J.B. Lippincott.
• Fantry, L. (2003). Chronic Infections of the Small Intestine. In Textbook of Gastroenterology, 4th edition(pp 1561-1580). Philadelphia: J.B. Lippincott.
• Fantry, L. (2002). Treponema Pallidum. In Antimicrobial Therapy and Vaccines(pp 749-758). Baltimore: Williams & Wilkins.
• Fantry, L. (1999). Ambulatory Care for the HIV-Infected Patient. In Principles of Ambulatory Medicine, 5th Edition(pp 425-456). Baltimore: Williams & Wilkins.
• Fantry, L. (1999). Chronic Infections of the Small Intestine. In Atlas of Gastroenterology, 2nd Edition(pp 276-279). Philadelphia: Lippincott.
• Fantry, L. (1999). Chronic Infections of the Small Intestine. In The Textbook of Gastroenterology, 3rd Edition(pp 1641-1659). Philadelphia: Lippincott.
• Fantry, L. (1999). Treponema Pallidum. In Antimicrobial Therapy and Vaccines, 1st Edition(pp 462-471). Williams & Wilkins.
• Fantry, L. (1995). Ambulatory Care for the HIV-Infected Patient. In Principles of Ambulatory Medicine (4th Edition). Baltimore: Williams & Wilkins.
• Fantry, L. (1992). Tuberculin Positivity among the Homeless. In Journal of Health Care for the Poor and Underserved(pp 263-269). Baltimore: Johns Hopkins University Press.
• Fantry, L. (1991). Hepatitis A.. In The Manual of Common Communicable Diseases in Shelters(pp 115-121). Boston: Boston Health Care for the Homeless Program.
• Fantry, L. (1991). Hepatitis B In:. In The Manual of Common Communicable Diseases in Shelters(pp 179-193). Boston Health Care for the Homeless Program.

Journals/Publications

• Fantry, L. (2021). Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond.. AIDS Res Hum Retroviruses, 37(2021 Apr;37(4):), 297-303. doi:0.1089/AID.2020.0263
  More info

  York LD, Fisher JM, Malladi L, August AA, Ellis KE, Marquez JL, Kaveti A, Khachatryan M, Paz MK, Adams MD, Bedrick EJ,
• Fantry, L., & Rokkam, V. (2021). COVID-19 Reinfection in An Immunosuppressed Patient Without An Antibody Response.. Am J Med Sci, 362(1), 103. doi:0.1016/j.amjms.2021.02.003
• Fantry, L. E., & Connick, E. (2019). The Internist's Role in Ending the HIV Epidemic in the United States. The American journal of medicine.
• Shende, T. C., Fisher, J. M., Perez-Velez, C. M., Guido, A. A., Sprowl, K. M., Drake, T. M., Adelus, M. L., Bedrick, E. J., & Fantry, L. E. (2019). PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona. Journal of community health.
  More info

  HIV pre-exposure prophylaxis (PrEP) is underutilized among Hispanics, women, and low-income individuals. To better understand PrEP barriers in this population, questionnaires were administered to 500 patients attending public health clinics in southern Arizona which provide family planning and sexually transmitted infections care. Sixty-three percent believed that they had no risk of HIV infection. When asked "Before today, did you know that there was a pill that can prevent HIV infection?" 80% of persons answered no. Among women, 88% answered no to this question. As expected, individuals with a higher perceived HIV risk (OR 1.76) or one HIV risk factor (OR 5.85) had a higher probability of knowledge. Among survey participants 87% would take a daily pill, 91% would visit a health-care provider every 3 months, and 92% would have laboratory testing every 3 months. Fifty-four percent would not be afraid or embarrassed if friends or family knew they were taking PrEP. Seventy-two percent would take PrEP despite temporary nausea. Sixty-two percent would pay ≥ $40 every 3 months for PrEP. Lack of knowledge, rather than patient attitudes, is the more important barrier to wider utilization of PrEP among individuals, especially women, attending public health clinics in Southern Arizona. Future efforts need to focus on education and access to PrEP in underserved populations including women and Hispanics.
• Bagchi, S., Burrowes, S. A., Fantry, L. E., Hossain, M. B., Tollera, G. H., Kottilil, S., Pauza, C. D., Miller, M., Baumgarten, M., & Redfield, R. R. (2017). Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population. SAGE pen medicine, 5, 2050312117725644.
  More info

  To determine factors associated with increased risk of developing cardiovascular disease in a high-risk patient population.
• Fantry, L. E., & Cleghorn, F. R. (2016). HHV-6 infection in patients with HIV-1 infection and disease. The AIDS reader, 9(3), 198-203, 221.
  More info

  Human herpesvirus 6 (HHV-6) is among the most widespread of the human herpesviruses. In immunocompetent children, it causes exanthem subitum, febrile episodes without skin rash, and non-Epstein-Barr and non-cytomegalovirus infectious mononucleosis. HHV-6 has also been associated with clinical disease in bone marrow and solid organ transplant recipients. Its potential role in HIV-1-associated clinical syndromes is now being recognized and evaluated. In this review, we describe the virus, the pathogenesis of HHV-6-associated disease, and the diagnostic tests used to differentiate active from latent infection. We then discuss possible clinical manifestations of HHV-6 in HIV-1-infected patients, how to evaluate the need for treatment, and which pharmacologic agents are potentially useful. There is no consensus on these issues in the medical community, and HHV-6 is not now included among indicator infections for the diagnosis of AIDS.
• Fantry, L. E., Nowak, R. G., Fisher, L. H., Cullen, N. R., Yimgang, D. P., Stafford, K. A., Riedel, D. J., Kang, M., Innis, E. K., Riner, A., Wang, E. W., & Charurat, M. E. (2016). Colonoscopy Findings in HIV-Infected Men and Women from an Urban U.S. Cohort Compared with Non-HIV-Infected Men and Women. AIDS research and human retroviruses, 32(9), 860-7.
  More info

  As HIV-infected patients live longer, non-AIDS-defining cancers are now a major cause of morbidity and mortality. The purpose of this study was to compare the prevalence, type, and location of colorectal neoplastic lesions found on colonoscopy in HIV-infected patients from an urban U.S. cohort with non-HIV-infected patients.
• Sowah, L. A., Buchwald, U. K., Riedel, D. J., Gilliam, B. L., Khambaty, M., Fantry, L., Spencer, D. E., Weaver, J., Taylor, G., Skoglund, M., Amoroso, A., & Redfield, R. R. (2016). Anal Cancer Screening in an Urban HIV Clinic: Provider Perceptions and Practice. Journal of the International Association of Providers of AIDS Care, 14(6), 497-504.
  More info

  In this article, we sought to understand the perceptions and practice of providers on anal cancer screening in HIV-infected patients. Providers in an academic outpatient HIV practice were surveyed. Data were analyzed to determine the acceptability and perceptions of providers on anal Papanicolaou tests. Survey response rate was 55.3% (60.7% among male and 47.4% among female providers). One-third of the providers had received screening requests from patients. Female providers had higher self-rated comfort with anal Papanicolaou tests, with a mean score of 7.1 (95% confidence interval [CI] 4.7-9.5) compared to 3.6 (95% CI 1.5-5.7) for male providers, P = .02. Sixty-seven percent of male providers and 37.5% of female providers would like to refer their patients for screening rather than perform the test themselves. Only 54.2% of our providers have ever performed anal cytology examination. Our survey revealed that not all providers were comfortable performing anal cancer screening for their patients.
• Dickinson, S. A., & Fantry, L. E. (2002). Use of dual-energy x-ray absorptiometry (DXA) scans in HIV-infected patients. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 11(4), 239-44.
  More info

  Multiple studies have demonstrated increased rates of osteopenia and osteoporosis in HIV-infected patients but there have been no published studies on current screening practices. We conducted a retrospective chart review of 2924 patients attending an urban HIV clinic. Thirty patients (1%) had dual-energy x-ray absorptiometry (DXA) scans. Patients undergoing DXA scans were more likely to be older, women, and have nondetectable HIV viral load and CD4 count ≥200. The most frequently cited indications for screening were perimenopausal or postmenopausal status and HIV infection. Of the patients screened, 96% had osteopenia or osteoporosis with a median T-score of -1.9 and a median of 3.8 osteoporosis risk factors in addition to HIV.  Of the 20 practitioners in the clinic, only 7 had patients with screening DXA scans. DXA scans are underutilized in the HIV population given the high rate of osteopenia and osteoporosis detected in this study.
• Fisher, L. H., Stafford, K. A., Fantry, L. E., Gilliam, B. L., & Riedel, D. J. (2015). Cancer Knowledge and Opportunities for Education Among HIV-Infected Patients in an Urban Academic Medical Center. Journal of cancer education : the official journal of the American Association for Cancer Education, 30(2), 319-26.
  More info

  HIV-infected patients frequently present with advanced stage cancer. It is possible that late stage presentation may be related to lack of cancer knowledge and/or barriers to care. Questionnaires were administered to 285 adult HIV-infected patients to evaluate knowledge of cancer risk factors and symptoms and barriers to care between 2011 and 2012. Differences in mean and percent scores by group were assessed using a t test for independent samples and chi-square analysis, respectively. Respondents were predominantly male (64%), African-American (86%), and low income (60% 
• Hodowanec, A., Nayak, S., Charurat, M., Vaughan, L., Kanno, M., & Fantry, L. (2012). Prevalence of asymptomatic bacterial sexually transmitted infections in hospitalized HIV patients in Baltimore City. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 11(1), 16-9.
  More info

  Sexually transmitted infections (STIs) are known to promote the transmission of HIV. Diagnosing these infections can identify patients engaging in high-risk behaviors and provides an opportunity for intervention and education. The Centers for Disease Control and Prevention (CDC) recommends STI screening as part of routine HIV care. Ninety HIV-infected inpatients admitted to the University of Maryland Hospital were screened for gonorrhea, chlamydia, and syphilis. None of the nucleic acid amplification probes were positive for gonorrhea, and 1 was positive for chlamydia. A total of 8 rapid plasma reagin (RPR) tests were positive, 2 of which are believed to be associated with new infection or treatment failure. Rapid plasma reagin positivity was found to be associated with men who have sex with men (MSM), low CD4 count, and high HIV viral load. Routine inpatient screening for asymptomatic STIs in HIV-infected patients may be beneficial, particularly patients not engaged in routine outpatient care.
• Lafferty, M. K., Fantry, L., Bryant, J., Jones, O., Hammoud, D., Weitzmann, M. N., Lewis, G. K., Garzino-Demo, A., & Reid, W. (2014). Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathogens and disease, 71(1), 81-9.
  More info

  Accelerated bone loss leading to osteopenia, osteoporosis, and bone fracture is a major health problem that is increasingly common in human immunodeficiency virus (HIV)-infected patients. The underlying pathogenesis is unclear but occurs in both treatment naïve and individuals receiving antiretroviral therapies. We developed an HIV-1 transgenic rat that exhibits many key features of HIV disease including HIV-1-induced changes in bone mineral density (BMD). A key determinant in the rate of bone loss is the differentiation of osteoclasts, the cells responsible for bone resorption. We found HIV-1 transgenic osteoclast precursors (OCP) express higher levels of suppressor of cytokine signaling-1 (SOCS-1) and TNF receptor-associated factor 6 (TRAF6) and are resistant to interferon-gamma (IFN-γ) mediated suppression of osteoclast differentiation. Our data suggest that dysregulated SOCS-1 expression by HIV-1 transgenic OCP promotes osteoclastogenesis leading to the accelerated bone loss observed in this animal model. We propose that elevated SOCS-1 expression in OCP antagonizes the inhibitory effects of IFN-γ and enhances receptor activator of NF-kB ligand (RANKL) signaling that drives osteoclast differentiation and activation. Understanding the molecular mechanisms of HIV-associated BMD changes has the potential to detect and treat bone metabolism disturbances early and improve the quality of life in patients.
• Riedel, D. J., Mwangi, E. I., Fantry, L. E., Alexander, C., Hossain, M. B., Pauza, C. D., Redfield, R. R., & Gilliam, B. L. (2013). High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS (London, England), 27(7), 1109-17.
  More info

  To determine mortality associated with a new cancer diagnosis in an urban, predominantly African-American, HIV-infected population.
• Gilliam, B. L., Chan-Tack, K. M., Qaqish, R. B., Rode, R. A., Fantry, L. E., & Redfield, R. R. (2006). Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS patient care and STDs, 20(11), 745-59.
  More info

  The combination of atazanavir (ATV) plus lopinavir/ritonavir (LPV/r) has been used in practice. However, clinical data supporting its use are limited. The objective of this study was to evaluate the efficacy and tolerability of regimens with ATV + LPV/r in protease inhibitor (PI)-susceptible and PI-resistant patients. A retrospective review of 2703 charts was performed to identify all patients who received ATV + LPV/r. From June 2003 to January 2005, 33 patients received ATV + LPV/r with nucleoside reverse transcriptase inhibitors (NRTIs) for 3 months or more. Virologic success (HIV-RNA < 400 copies per milliliter) was achieved in 30 patients (91%) in a median of 10 weeks (range, 2-68). Nineteen of the 23 patients (83%) who had ultrasensitive viral load (VL) assays were nondetectable. Among patients with 6 or more protease resistance (PR) mutations (PI-resistant), 11 of 14 (79%) achieved virologic success. Eleven of those received phenotypic testing (10 Virtual Phenotype, VircoLab, Baltimore, MD). Despite predicted phenotypic resistance to ATV (6 patients) and LPV/r (7 patients), virologic success was achieved in 4 of 6 (67%) and 4 of 7 (57%), respectively. The 3 PI-resistant patients who were virologic failures had extensive prior LPV/r use, 8-11 PR mutations, and predicted phenotypic resistance to LPV/r, but 2 of 3 had CD4 increases with ATV + LPV/r. Overall, 28 patients (85%) continue to tolerate ATV + LPV/r for a median of 32 weeks follow-up (range, 12-76). Combination ATV + LPV/r with NRTIs appears safe, tolerable, and efficacious in PI-resistant patients (>/=6 PR mutations) and predicted phenotypic resistance to ATV and LPV/r. Further studies of ATV + LPV/r in HIV-treatment are warranted.
• Fantry, L. E., Zhan, M., Taylor, G. H., Sill, A. M., & Flaws, J. A. (2005). Age of menopause and menopausal symptoms in HIV-infected women. AIDS patient care and STDs, 19(11), 703-11.
  More info

  The objective of this study was to examine the median age of menopause, factors associated with postmenopausal status, and the prevalence of menopausal symptoms in HIV-infected women. We surveyed 120 HIV-infected women between 40 and 57 years old who attended an inner city infectious diseases clinic. Ninety-five percent of the women surveyed were African American and almost half of the women (44%) had used methadone, heroin, cocaine, marijuana, or a combination of these drugs within the past 6 months. Eighty-seven percent had smoked cigarettes at least some time during their life and 45% drank alcohol between the ages of 40 and 49 years old. Thirty women were postmenopausal (having no menstrual periods in the previous 12 consecutive months), 31 were perimenopausal (having 1-11 periods within the previous 12 months), and 59 were premenopausal (having 12 or more periods within the previous 12 months). The median age of menopause was 50 years old (95% confidence interval = 49, 53). In a multivariate model, methadone use within the past 6 months was associated with postmenopausal status. We did not find an association between postmenopausal status and body mass index, number of pregnancies, CD4 cell counts, HIV viral load, individual and grouped antiretroviral therapies, cigarette smoking, and current or past oral contraceptive use. In multivariate analysis, postmenopausal status was associated with hot flashes and cocaine use was associated with vaginal dryness.
• Mehta, S., & Fantry, L. (2005). Gastrointestinal infections in the immunocompromised host. Current opinion in gastroenterology, 21(1), 39-43.
  More info

  Infections of the gastrointestinal tract are an important cause of morbidity and mortality in immunocompromised patients. This review summarizes the most important articles published between July 2003 and June 2004 in the pathogenesis, diagnosis, and treatment of gastrointestinal infections in the immunocompromised host.
• Sajadi, M. M., Fantry, G. T., & Fantry, L. E. (2004). A Czech researcher and Pneumocystis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39(2), 218, 270-1.
• Cade, W. T., Fantry, L. E., Nabar, S. R., & Keyser, R. E. (2003). Decreased peak arteriovenous oxygen difference during treadmill exercise testing in individuals infected with the human immunodeficiency virus. Archives of physical medicine and rehabilitation, 84(11), 1595-603.
  More info

  To determine if arteriovenous oxygen difference was lower in asymptomatic individuals with human immunodeficiency virus (HIV) infection than in sedentary but otherwise healthy controls.
• Cade, W. T., Fantry, L. E., Nabar, S. R., Shaw, D. K., & Keyser, R. E. (2003). A comparison of Qt and a-vO2 in individuals with HIV taking and not taking HAART. Medicine and science in sports and exercise, 35(7), 1108-17.
  More info

  The aim of this study was to determine whether highly active antiretroviral therapy (HAART), rather than the direct effect of HIV infection, limits peripheral muscle oxygen extraction-utilization (a-vO(2)) in individuals infected with the human immunodeficiency virus (HIV).
• Cade, W. T., Fantry, L. E., Nabar, S. R., Shaw, D. K., & Keyser, R. E. (2003). Impaired oxygen on-kinetics in persons with human immunodeficiency virus are not due to highly active antiretroviral therapy. Archives of physical medicine and rehabilitation, 84(12), 1831-8.
  More info

  To determine the effects of human immunodeficiency virus (HIV) and highly active antiretroviral therapy (HAART) on oxygen on-kinetics in HIV-positive persons.
• Fantry, L. (2003). Gastrointestinal infections in the immunocompromised host. Current opinion in gastroenterology, 19(1), 37-41.
  More info

  Persons with HIV infection, leukemia, lymphoma, solid organ and bone marrow transplants, and inherited immune deficiencies as well as those on immunosuppressive drugs are at high risk for infections of the gastrointestinal tract. Pathogenic as well as opportunistic viruses, bacteria, fungi, and protozoa cause infections in the esophagus, stomach, small intestine, and large intestine. Symptoms may be mild but more often are severe and even life threatening. This article reviews what is new in the field of gastrointestinal infections in the immunocompromised host during the past year. I will place specific emphasis on articles that are most pertinent to clinical care.
• Fantry, L. E. (2003). Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality. Journal of acquired immune deficiency syndromes (1999), 32(3), 243-4.
• Fantry, L. (2002). Gastrointestinal infections in the immunocompromised host. Current opinion in gastroenterology, 18(1), 34-9.
  More info

  Immunocompromised patients, including patients with AIDS, solid organ and bone marrow transplant recipients, patients with leukemia and lymphoma, patients with inherited immune deficiencies, and patients on immunosuppressive therapy for a variety of disorders, are at risk for infections-particularly opportunistic infections, which, by definition, do not infect the healthy host. All systems of the body, including the gastrointestinal tract, are susceptible. The esophagus, stomach, small intestine, and large intestine are sites of infection for viruses, bacteria, fungi, and protozoa. Symptoms can range in severity from fevers of unknown etiology to life-threatening hemorrhage and perforation. This review summarizes recent case reports, clinical studies, and reviews pertaining to pathogens that uniquely cause disease, more frequently cause disease, or cause more severe disease in the immunocompromised host than in the immunocompetent host.
• Fantry, L. E., & Staecker, H. (2002). Vertigo and abacavir. AIDS patient care and STDs, 16(1), 5-7.
  More info

  Vertigo can cause significant morbidity and make a person unable to perform activities of daily life. A human immunodeficiency virus (HIV)-infected patient experienced vertigo while taking abacavir that resolved immediately on cessation of therapy. The mechanism by which abacavir appeared to be associated with vertigo in this patient is unknown.
• Fantry, L. E., & Sun, C. J. (2002). Mycobacterium avium complex-associated cholecystitis in an HIV-infected woman. AIDS patient care and STDs, 16(5), 201-4.
  More info

  Mycobacterium avium complex (MAC) is commonly associated with fever, fatigue, nausea, diarrhea, and cytopenias related to invasion of the intestine and bone marrow. Infection and clinical disease has been reported in other organs as well. We report the first case of cholecystitis associated with MAC infection of the gallbladder.
• Fantry, L. (2001). Gastrointestinal infections in the immunocompromised host. Current Opinion in Gastroenterology, 17(1), 40-45.
  More info

  The gastrointestinal tract is a common site of infection in the opportunistic host. Pathogens range from highly virulent organisms, which infect people with well functioning immune systems as well as people with poorly functioning immune systems, to opportunistic organisms, which infect only those with impaired immune systems. Viruses, bacteria, fungi, and protozoa lead to disease that can be especially severe, debilitating, and difficult to treat in the immunocompromised host. Yet in this era of highly active antiretroviral therapy for HIV-infected patients and strategies to reduce immunosuppression in transplant and oncology patients, appropriate diagnostic tests and treatment can both improve the quality of life and decrease mortality. In this article, I review the changing pathogenesis, epidemiology, clinical presentation, diagnosis, and treatment of gastrointestinal infections in the immunocompromised host.
• Fantry, L. (2000). Gastrointestinal infections in the immunocompromised host. Current Opinion in Gastroentergology, 16(1), 45-50.
  More info

  Infectious diseases of the gastrointestinal tract continue to be an important source of morbidity and mortality. Viruses, bacteria, fungi, and protozoa that infect normal hosts also infect the gastrointestinal tract in immunocompromised hosts. Disease caused by these pathogens may be more severe and more difficult to treat in immunocompromised hosts. In addition, pathogens that rarely cause disease in normal hosts cause significant disease in immunosuppressed hosts. Diagnostic decisions need to take into account expected pathogens and response to therapy. Treatment decisions must be based on the findings of diagnostic procedures; expected pathogens; and recent data suggesting that highly active antiretroviral therapy, with its ability to reconstitute immune function, is an essential component of treatment. This review summarizes the most important developments made in the pathogenesis, clinical presentation, diagnosis, and treatment of gastrointestinal infections in immunocompromised hosts in the past year.
• Fantry, L. (1996). Early Intervention for Human Immunodeficiency Virus in Baltimore Sexually Transmitted Diseases Clinics: Impact on Gonorrhea Incidence in Patients Infected With HIV. Sex Transmitted Disease, 23(5), 370-377.
  More info

  Conclusions: Providing clinical care to persons with HIV may facilitate the reduction of high-risk behaviors that lead to incident STDs and further HIV transmission.
• Fantry, L. (1995). Immunodeficiency and Elevated CD4+ Cell Counts in Two Patients Co-Infected with HIV and HTLV-1.. Clinical Infectious Disease, 21(6), 1466-8.
  More info

  Lori Fantry, Eric De Jonge, Paul G. Auwaerter, & Lederman, H. (1995). Immunodeficiency and Elevated CD4 T Lymphocyte Counts in Two Patients Coinfected with Human Immunodeficiency Virus and Human Lymphotropic Virus Type I. Clinical Infectious Diseases, 21(6), 1466-1468. Retrieved from http://www.jstor.org/stable/4459106

Poster Presentations

• Lim, J., Fisher, J. M., Sadoway, D., Gupte, R., Nandemi, P., Joseph, M., Loveland, M., Guido, A., Madhivanan, P. P., Bedrick, E. J., & Fantry, L. E. (2022, Fall semester). Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona. ID Week. Washington, DC: Infectious Disease Society of America.
  More info

  Study of PrEP knowledge
• Fantry, L., & Gurm, G. (2010, July). Poor renal function and low CD4 count associated with cyocardial ischemia in HIV patients. XIII International AIDS Conference,. Vienna Austria.
• Fantry, L., Pons, S., & Anderson, E. (2007, June). Has Your Partner Been Tested? Counseling and Testing in an HIV Primary Care Clinic. The American Conference for Treatment of HIV. Dallas TX: The American Conference for Treatment of HIV.
• Fantry, L., Gilliam, B. L., Chan-Tack, K. M., Qaqish, R. B., Rode, R. B., & Redfield, R. R. (2005, Oct). Successful Treadment with Atazanavir (ATV) and Lopinavir/ritonavir (LPV/r) Combination Theraphy in Protease Inhibitor (PI)- Susceptible and PI-Resistant HIV-Infected Patients. IDWeek 2005. San Francisco, CA: Infectious Disease Society of America.
• Fantry, L., Wolff, T., & Taylor, G. (2004, April). The Use of HPV in HIV-Infected Women with ASCUS Pap. Eighth International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD: National Cancer Institute.
• Fantry, L., Zhan, M., Taylor, G., Sill, A. M., & Flaws, J. A. (2004, July). Menopause and HIV-Infected Women. XV International AIDS Conference. Bangkok Thailand: International AIDS Society.

Reviews

• Fantry, L. (1999. HHV-6 infection in patients with HIV-1 infection and disease.(pp 198-203). The AIDS Reader.